We are live on ! Find out more
PTHS

Pelthos Therapeutics
PTHS

5 hedge funds and large institutions have $187K invested in Pelthos Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

7.49% less ownership

Funds ownership: 9.77% → 2.28% (-7.5%)

44% less funds holding

Funds holding: 9 → 5 (-4)

78% less capital invested

Capital invested by funds: $846K → $187K (-$659K)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
5
Holders Change
-4
Holders Change %
-44.44%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$165K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$447
3
Bank of America
Bank of America
North Carolina
+$12

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$626K
2
BFM
Boothbay Fund Management
New York
-$186K
3
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services
Minnesota
-$14.8K
4
TRCT
Tower Research Capital (TRC)
New York
-$2.99K
5
UBS Group
UBS Group
Switzerland
-$422

PTHS Hedge Fund Activity: Q2 2025 in Review

5 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q2 2025, worth a combined $187K — down 78% from $846K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PTHS and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $165K. The largest seller was Ikarian Capital, exiting entirely with an estimated $626K sold.

  • 5 institutional investors held Pelthos Therapeutics (PTHS) as of Q2 2025, down from 9 in Q1 2025.
  • Funds reported $187K of Pelthos Therapeutics stock for Q2 2025, down 78% quarter-over-quarter.
  • 1 fund opened new Pelthos Therapeutics positions in Q2 2025 and 5 closed out, a net change of -4 holders.
  • The largest Pelthos Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $165K added.
  • The largest Pelthos Therapeutics seller in Q2 2025 was Ikarian Capital, an estimated $626K sold.

Based on aggregated 13F filings for Q2 2025.